SuspendedPhase 1NCT02949414

A Study to Assess the Safety, Tolerability and Potential Efficacy of a Tracheal Replacement Consisting of a Tissue-engineered Tracheal Scaffold With Seeded Mesenchymal Cells

Studying Congenital tracheal stenosis

Last synced from ClinicalTrials.gov May 7, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Cell Therapy Catapult
Principal Investigator: Martin Birchall, MD, PhD
University College, London
Intervention: Cadaveric decellularised tracheal scaffold seeded with autologous mesenchymal cells(procedure)
Enrollment: 4 enrolled
Eligibility: 18 years · All sexes
Timeline: 2016 – 2024

Study locations (1)

Royal Nose Throat and Ear Institute, London, United Kingdom

Collaborators

University College, London · Videregen Limited

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02949414 on ClinicalTrials.gov

← Back to all trials